

1 Article

2 CLOT STIFFNESS MEASURED BY SEER 3 SONORHEOMETRY AS A MARKER OF POOR 4 PROGNOSIS IN HOSPITALIZED COVID-19 PATIENTS

5

6 Francisco José López-Jaime*, Sandra Martín-Téllez*, Alberto Doblas-Márquez*, Ignacio Márquez-Gómez†,
7 José María Reguera-Iglesias‡, Manuel Isidro Muñoz-Pérez*, Ihosvany Fernández-Bello‡, Adrián Montaña*.

8 *Unidad de Hemostasia y Trombosis, Hospital Universitario Regional de Málaga, IBIMA, Málaga, Spain;
9 franlopezjaime@gmail.com (F.J.L.J.); sandra.martint@gmail.com (S.M.-T); albertodoblas93@gmail.com (A.D.-M.);
10 misidro.munoz.sspa@juntadeandalucia.es (M.I.M.-P.)

11 †Servicio de Enfermedades Infecciosas, Hospital Universitario Regional de Málaga, Málaga, Spain;
12 nacho.marquez83@gmail.com (I.M.-G.); jmreguera99@yahoo.com (J.M.R.-I)

13 ‡Biopharm, Novo Nordisk, Madrid, Spain; IHFE@novonordisk.com (I.F.-B)

14

15 Correspondence: adrianmo18@gmail.com (A.M.) Tel.: + 34 951291085

16

17 SUMMARY:

18

19 **Background:** High incidence of life-threatening thrombotic complications is observed in severely ill
20 COVID-19 patients. D-dimer may help evaluate disease severity and predict outcomes at hospital
21 admission. However, its non-specificity and long analysis times strongly constrain its clinical value.
22 Viscoelastic tests (VET) are widely available rapid point-of-care devices that have been shown to detect a
23 hypercoagulable state (increased clot stiffness and fibrinolysis shutdown) as major contributors of the
24 thrombotic complication in COVID-19. Nevertheless, based on the data obtained so far, definitive
25 conclusions have not been drawn.

26 **Objectives:** We aim to evaluate the association between VET parameters, standard coagulation tests and
27 inflammation markers assessed in COVID-19 patients at hospital admission with disease severity and
28 outcomes.

29 **Patients/Methods:** A total of 69 COVID-19 patients requiring hospitalization were included in the study.
30 The pro-inflammatory and pro-thrombotic state was analyzed by a panel of inflammation markers (IL-6,
31 CRP, LDH, ferritin), routine coagulation tests (PT, aPTT, platelet count, fibrinogen, D-dimer) and a SEER
32 sonorheometry VET profile (Quantra® System).

33 **Results:** Inflammatory markers IL-6, CRP, LDH and ferritin were elevated in a high percentage of patients
34 (73.6%, 89.2%, 57.1% and 52.4%), as were coagulation-related parameters such as fibrinogen (81.4%) and
35 D-dimer levels (66.2%). Quantra® analysis revealed increased clot stiffness (CS) in 34.8%, particularly due
36 to increased fibrinogen contribution (FCS) in 63.7%. Increased clot stability to lysis (CSL) was observed
37 in 32.4%. Age > 65 years, elevated values of fibrinogen, D-dimer, LDH, increased clot stiffness and
38 resistance to clot lysis were significantly associated with worsening disease. The Quantra® FCS parameter
39 showed a particularly high prognostic value in distinguishing patients with severe symptomatology.

40 **Conclusion:** The global study of hemostasis by the whole blood point-of-care Quantra® VET system may
41 be a powerful tool for identifying poor prognosis in COVID-19 patients at hospital admission. In particular,
42 FCS measured by Quantra® could be established as a plausible prognostic marker to aid the clinical
43 management of COVID-19 patients.

44

45 **KEYWORDS:** Quantra, thrombosis, viscoelastic tests, COVID-19

46

47

48

49

50 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

51 **1. INTRODUCTION**

52

53 At the moment of writing this article, coronavirus disease 2019 (COVID-19) caused by severe acute
54 respiratory syndrome coronavirus 2 (SARS-CoV-2) has already killed more than 3 million people
55 worldwide [1]. The development of an extreme inflammatory response and prothrombotic state is
56 associated with poor prognosis and remains the major cause of the high morbidity and mortality rate
57 associated with this condition [2,3].

58 Previous studies on the hemostatic status of COVID-19 patients identified several parameters such as
59 fibrinogen and D-dimer that could be established as markers of thrombotic risk and helped in the clinical
60 management of patients [3–5]. Elevated D-dimer levels (>1000 ng/mL) have also been proposed as an
61 indicator of risk for pulmonary embolism [6]. However, these parameters have drawbacks that affect their
62 reliability and clinical use to predict outcomes in COVID-19. D-dimer in particular has important
63 limitations that raises questions on its true prognostic value for thrombosis in COVID-19. Although highly
64 elevated levels of D-dimer in COVID-19 have been attributed to acute lung injury with intra-alveolar fibrin
65 deposition and subsequent breakdown of this extravascular fibrin, D-dimer values may be elevated for a
66 variety of reasons and therefore increased values are not only indicative of increased thrombotic risk [7–
67 10]. In addition, D-dimer requires a long time of analysis which together weaken its clinical value and
68 reveals the need to identify new biomarkers that provide a rapid and effective assessment of thrombotic
69 risk in COVID-19.

70 Viscoelastic tests (VET) are recognized powerful tools for the rapid identification and characterization
71 of hypercoagulable state in infectious diseases and several groups have already evaluated the use of VET
72 in COVID-19 patients [11,12]. In general, the available data indicate a high frequency of increased clot
73 stiffness and fibrinolysis shutdown but with weak evidence on the association of this hypercoagulable
74 profile with disease severity. Larger studies with larger numbers of patients are therefore needed to confirm
75 these important findings.

76 Sonic Estimation of Elasticity by Resonance (SEER) sonorheometry (Quantra® system) is a novel
77 ultrasound-based VET technology [13]. With this system, a hypercoagulable profile has been reported in
78 hospitalized COVID-19 patients [14,15]. The objective of this study is to investigate whether the Quantra
79 parameters, as well as a panel of inflammation markers and routine coagulation tests, are associated with
80 disease severity and outcomes of hospitalized COVID-19 patients.

81

82 **2. MATERIALS AND METHODS**

83

84 *2.1 Patients and diagnosis criteria*

85

86 A total of 69 patients, positive for SARS-CoV-2 by PCR and hospitalized at the Regional University
87 Hospital of Málaga were included in the study. All patients were over 18 years of age and none had any
88 other hemostasis disorders. Immunocompromised patients, such as oncology patients on chemotherapy or
89 those positive for HIV were also excluded from the study.

90 Patients were classified according to disease severity (critical, severe, and non-severe) based on the
91 World Health Organization (WHO) criteria [16]. Briefly, critical COVID-19 patients were those who
92 presented sepsis, septic shock or other conditions that required provision of life-sustaining therapies
93 (mechanical ventilation or vasopressor therapy); severe were those with oxygen saturation <90% on room
94 air or respiratory rate >30 breaths/min or with signs of severe respiratory distress including the need to use
95 accessory muscles and the inability to formulate full sentences; and finally, the absence of any critical or
96 severe COVID-19 criteria was considered as non-severe disease. Patients were also classified according to
97 the presence or absence of adverse events, including the need for mechanical ventilation, development of
98 encephalitis, thrombotic events, admission to ICU (intensive care unit) or death. The study was approved
99 by the local ethical committee. Written informed consent was obtained from patients or legal guardians
100 before inclusion.

101

102 *2.2 Inflammatory and procoagulant status*

103

104 Citrated, EDTA and non-anticoagulated blood samples were drawn on hospital admission and after
 105 confirmation of SARS-CoV-2 infection. Quantra[®] Hemostasis Analyzer (HemoSonics, Charlottesville,
 106 VA, USA) was used to evaluate the global viscoelastic hemostatic status of the patients. On this system,
 107 QStat[®] and QPlus[®] cartridges were used to determine the following parameters: Clot Time (CT),
 108 Heparinase Clot Time (CTH), Clot Time Ratio (CTR: CT/CTH), Clot Stiffness (CS), Fibrinogen
 109 Contribution to Clot Stiffness (FCS), Platelet Contribution to Clot Stiffness (PCS), Clot Stability to Lysis
 110 (CSL). Details of Quantra QPlus and QStat cartridges have been described previously [17,18]. Complete
 111 blood count, prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin
 112 time (aPTT), D-dimer, fibrinogen, IL-6, ferritin, lactate dehydrogenase (LDH) and C-reactive protein
 113 (CRP) were also determined.

114

115 2.3 Statistical analysis

116

117 The statistical software "SPSS statistics" (IBM) was used for the analysis. Comparison for qualitative
 118 (Chi-square test or Fisher's Exact Test) and quantitative differences (Mann-Whitney U test) were applied.
 119 Relationship between parameters at admission and disease severity or adverse events was assessed by ROC
 120 curve analysis.

121

122

123 3. RESULTS

124

125 3.1 Demographic and clinical characteristics of the patients

126

127 Table 1 and supplementary file 1 show demographic and clinical characteristics of the patient cohort:
 128 44.9% of patients developed non-severe disease, 39.1% severe disease and 16% critical disease. Compared
 129 to non-severe patients, severe/critical patients were older, often female and had more diabetes and adverse
 130 events. A total of 26.1% of the patients had an adverse event during hospital admission. Except for
 131 encephalitis, all adverse events occurred in the severe/critical group.

132

133 **Table 1. Demographic and clinical characteristics of COVID-19 patients with non-severe disease versus**
 134 **severe/critical disease.**

	Total (N=69) N (%)	Non-severe (N=31) N (%)	Severe/Critical (N=38) N (%)	P-value (*)
Age				
>65 years	34 (49.3)	10 (32.3)	24 (63.1)	0.011
<65 years	35 (50.7)	21 (67.7)	14 (36.8)	
Sex				
Male	38 (55)	23 (74.2)	15 (39.5)	0.004
Female	31 (45)	8 (25.8)	23 (60.5)	
Past medical history				
Hypertension	32 (46.4)	11 (35.5)	21 (55.3)	0.101
Diabetes	19 (27.5)	4 (12.9)	15 (39.5)	0.014
Coronary heart disease	10 (14.5)	4 (12.9)	6 (15.8)	1.000
COPD	7 (10.1)	2 (6.5)	5 (13.2)	0.446
Adverse event				
Mechanical ventilation	18 (26.1)	1 (3.2)	17 (44.7)	<0.001
ICU admission	13 (18.8)	0 (0)	13 (34.2)	<0.001
Encephalitis	5 (7.2)	0 (0)	5 (13.2)	0.060
Thrombotic event	1 (1.4)	1 (3.2)	0 (0)	0.449
Death	3 (4.3)	0 (0)	3 (7.9)	0.247
	4 (5.8)	0 (0)	4 (10.5)	0.122

135

136

137

138

139

(*) Non-severe vs. severe/critical by Chi-square test and Fisher's Exact Test. COPD: chronic obstructive pulmonary disease.

3.2 Increased clot stiffness in patients with poor prognosis.

140 As shown in Table 2, patients with adverse events showed significantly higher values of CRP, LDH,
 141 fibrinogen, D-dimer and the Quantra clot stiffness parameter FCS.

142
 143
 144

Table 2. Median of inflammation and tissue damage markers, coagulation and Quantra® parameters in patients with and without adverse events.

	No adverse events		Adverse events		P-value (*)
	N	Median (IQR)	N	Median (IQR)	
Inflammation and tissue damage					
IL-6 (pg/mL)	38	16.7 (0 - 1874)	15	6.8 (0 - 88)	0.239
CRP (mg/L)	47	44.9 (0 - 236)	18	94.8 (23 - 174)	0.015
LDH (IU/L)	45	234 (125 - 404)	18	308.5 (100 - 1716)	0.024
Ferritin (ng/mL)	45	211 (87 - 847)	18	413.8 (39 - 1365)	0.726
Coagulation					
PT (sec)	51	11.6 (11 - 18)	18	12.1 (11 - 13)	0.897
aPTT (sec)	51	25.2 (18 - 30)	18	24.6 (20 - 27)	0.951
Fibrinogen (mg/dL)	44	554 (215 - 900)	15	730.7 (532 - 900)	0.022
Platelet count ($\times 10^3/\mu\text{L}$)	51	199 (130 - 401)	18	238 (133 - 479)	0.929
D-dimer ($\mu\text{g/L}$)	50	611 (175 - 9915)	17	824.5 (300 - 3406)	0.043
Quantra®					
CT (sec)	51	137 (93 - 179)	18	143.5 (125 - 159)	0.816
CTH (sec)	50	123 (86 - 152)	18	129.5 (110 - 160)	0.522
CS (hPa)	51	26 (11 - 47)	18	36.1 (19 - 62)	0.058
PCS (hPa)	51	22.8 (10 - 38)	18	30.9 (15 - 48)	0.063
FCS (hPa)	51	3.7 (1 - 12)	18	6.2 (4 - 14)	0.018
CSL (%)	26	98 (88 - 100)	11	100 (91 - 100)	0.169

IQR: interquartile range; (*) Mann-Whitney U-test.

145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162

Table 3 shows the proportion of elevated levels of all assessed parameters, defined as the proportion above the upper limit of normal (ULN), in the total cohort as well as in patients who did not experience an adverse event and those who did. Inflammation and tissue damage markers were elevated in at least half of the patients: IL-6 in 73.6%, CRP in 89.2%, LDH in 57.1% and ferritin in 52.4%. Regarding coagulation parameters, shortened PT and aPTT clot times, i.e., below the lower limit of normal (LLN), were only observed in 0% and 14.5%, respectively. An elevated platelet count was only present in 8.7% of all patients. In contrast, fibrinogen and D-dimer were elevated in 81.4% and 66.2%, respectively. On the Quantra system, shortened CT and CTH clot times (below LLN) were only observed in 8.7% and 14.7%, respectively. Total clot stiffness (CS) was elevated in 34.8%, with an elevated PCS and FCS in 27.6% and 63.7%, respectively. A CSL value of 100% (suggesting absence of fibrinolysis) was observed in 32.4%.

Table 3. Markers of inflammation and tissue damage, coagulation and Quantra parameters: proportion above upper limit of normal (ULN) or below the lower limit of normal (LLN) in COVID-19 patients with no adverse events versus those with adverse events. In the case of PT, aPTT, CT and CTH, the percentage of patients with times below the lower limit of normal values was considered.

Test	ULN/ BLN	N/total (%)	No adverse events	Adverse events	P-value (*)
			N/total (%)	N/total (%)	
Inflammation and tissue damage					
IL-6 (pg/mL)	4.4	39/53 (73.6)	28/38 (73.7)	11/15 (73.3)	1.000
CRP (mg/L)	5.0	58/65 (89.2)	41/47 (87.2)	17/18 (94.4)	0.663
LDH (IU/L)	246	36/63 (57.1)	21/45 (46.7)	15/18 (83.3)	0.008
Ferritin (ng/mL)	388	33/63 (52.4)	22/45 (48.9)	11/18 (61.1)	0.380
Coagulation					
PT (sec)	10.0	0/69 (0)	0/51 (0)	0/18 (0)	1.000
aPTT (sec)	20.6	10/69 (14.5)	8/51 (15.7)	2/18 (11.1)	1.000
Platelet count ($\times 10^3/\mu\text{L}$)	450	6/69 (8.7)	5/51 (9.8)	1/18 (5.6)	1.000
Fibrinogen (mg/dL)	400	48/59 (81.4)	34/44 (77.3)	14/15 (93.3)	0.259
D-dimer ($\mu\text{g/L}$)	500	45/68 (66.2)	29/50 (58)	16/18 (88.9)	0.018
Quantra®					
CT (sec)	113	6/69 (8.7)	3/51 (5.9)	2/18 (11.1)	0.600
CTH (sec)	109	10/68 (14.7)	7/50 (14)	3/18 (16.7)	0.717
CS (hPa)	33.2	24/69 (34.8)	14/51 (27.4)	10/18 (55.6)	0.031


PCS (hPa)	29.8	19/69 (27.6)	11/51 (21.6)	8/18 (44.4)	0.074
FCS (hPa)	3.7	44/69 (63.7)	28/51 (54.9)	16/18 (88.9)	0.008
CSL (%)	100	12/37 (32.4)	5/26 (19.2)	7/11 (63.6)	0.018

(*) Non-severe vs. severe/critical by Chi-square test and Fisher's Exact Test.

163
164
165
166
167
168
169
170
171
172
173
174
175
176
177

Only, LDH, D-dimer, the Quantra clot stiffness parameters (CS and FCS) and resistance to lysis (CSL) showed a significantly higher proportion of elevated values in COVID-19 patients with no adverse events compared with those with adverse events. Patients with elevated FCS values together with elevated D-dimer values were significantly associated with the presence of an adverse event ($P<0.001$).

In predicting the severity of disease, the area under the curve (AUC) by ROC analysis was 0.720 with a 95% confidence interval of [0.546 – 0.895] ($P=0.038$) for FCS; 0.581 [0.379 – 0.783] ($P=0.443$) for LDH; 0.635 [0.439 – 0.831] ($P=0.203$) for D-dimer; 0.673 [0.485 – 0.860] ($P=0.104$) for CS and 0.538 [0.336 – 0.739] ($P=0.722$) for CSL. In predicting the manifestation of an adverse event, the AUC was 0.715 [0.541 – 0.888] ($P=0.047$) for FCS; 0.645 [0.440 – 0.849] ($P=0.181$) for LDH; 0.562 [0.361 – 0.763] ($P=0.567$) for D-dimer; 0.657 [0.451 – 0.863] ($P=0.147$) for CS and 0.643 [0.422 – 0.863] ($P=0.188$) for CSL. Thus, only FCS showed the highest significant AUC compared to the other variables such as D-dimer, as shown in figure 1 ($P=0.003$).




178
179
180
181
182
183
184
185
186
187
188
189
190
191
192

Figure 1. ROC analysis. A) ROC curve of FCS and D-dimer at admission in predicting severity of disease. **B)** ROC curve of FCS and D-dimer at admission in predicting the manifestation of an adverse event.

3.3 Close interaction between procoagulant status and inflammation in COVID-19 patients.

FCS values showed a strong correlation with plasma fibrinogen ($r=0.850$; $P<0.001$). In turn, both parameters showed a moderate to strong correlation with CRP values (0.699; $P<0.001$ for FCS and 0.803; $P<0.011$ for plasma fibrinogen). Elevated FCS and plasma fibrinogen values were significantly associated with elevated CRP values ($P=0.008$ and $P<0.001$, respectively) and IL-6 values ($P=0.028$ and $P<0.001$, respectively). On the other hand, PCS correlated strongly with platelet count ($r=0.752$; $P<0.001$) (Figure 2).



193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238

Figure 2. Scatter plots and Spearman correlation. FCS vs. fibrinogen (left) and CRP (middle); PCS vs. platelet count (right).

4. DISCUSSION

We present the results of a pilot study in which we evaluated the use of global viscoelastic hemostatic analysis by sonorheometry (Quantra system) in COVID-19 patients on admission and the association of the Quantra parameters with disease severity and outcomes. Whole blood samples from 69 COVID-19 patients were analyzed using standard laboratory tests for coagulation, inflammatory and tissue damage markers and the Quantra Hemostasis Analyzer. Global hemostatic analysis by the Quantra revealed increased clot stiffness in a high number of COVID-19 patients, especially in those who experienced an adverse event during admission, such as the need for mechanical ventilation, development of encephalitis, thrombotic event, ICU admission or death. Particularly the FCS value was shown to indicate poor prognosis and could be of great use in the clinical management of these patients, both in triage and in the development of new therapeutic approaches.

Of the total cohort, 55.1% were classified as having severe/critical disease according to WHO criteria [16]. As expected, all patients who experienced an adverse event belonged to this group, except for one patient in the non-severe disease group who developed encephalitis. The most occurring event was the presence of ARDS observed in 18.8% of patients, who required mechanical ventilation. Consistent with previous studies, we observed that an age > 65 years was indicative of a worse prognosis [19,20]. Thus, patients with advanced age were more frequently observed in the severe/critical disease group. Other comorbidities such as diabetes were also associated with a worse prognosis as previously described [21,22].

We observed in our series a high proportion of patients with IL-6 and CRP values above the ULN. In support of our finding, these markers have been shown to be elevated in COVID-19 patients, especially in those with ARDS [5]. In fact, the group of Herold. et al. demonstrated the value of these parameters as predictors of the need for mechanical ventilation. Elevated fibrinogen levels were also associated with elevated Il-6 values, thus establishing a clear interaction between coagulation and inflammation, as reported in the study by Ranucci et al [14]. This is further evidence in support of the concept of immunothrombosis as a pathogenetic mechanism in COVID-19 [20]. A high percentage of patients in our cohort also showed LDH values above ULN, especially in those associated with worse prognosis, consistent with lung damage due to pneumonia caused by SARS-CoV-2 infection and which has been associated with increased patient mortality [23].

Regarding coagulation parameters, COVID-19 patients showed elevated levels of fibrinogen and D-dimer, the latter being mostly observed in patients who experienced an adverse event during admission. These results are also in agreement with those reported in the literature, which propose these factors as probably responsible for the thrombotic events that have been observed in COVID-19 patients [3,4].

VET analysis has also been proposed as a powerful tool for the study of the global hemostatic status of COVID-19 patients [24]. Especially, these studies have focused on the analysis of patients with poor prognosis such as those admitted to the ICU or with ARDS, revealing that VET analysis could be established as a promising tool to predict thrombotic complications and thus optimize the diagnosis and treatment of COVID-19 patients [25]. Our results showed that a high percentage of patients had altered parameters of clot stiffness, mainly due to the contribution of fibrinogen. Alterations in these parameters were significantly more prevalent in patients with an adverse event during admission. These results support previous studies suggesting that the hypercoagulability of COVID-19 patients is largely attributable to the contribution of fibrin and platelets to clot stability and stiffness [14].

239 As expected, platelet count and fibrinogen levels correlated positively with PCS and FCS values,
240 respectively. However, despite the high correlation between platelet count and PCS, an elevated platelet
241 count was observed in only 8.7% of patients, compared to 27.6% of patients with an elevated PCS. This
242 result supports the evidence shown by Baryshnikova et al., that PCS is not only influenced by platelet count,
243 but also by platelet functionality [26]. Furthermore, these findings highlight that platelet hyperreactivity
244 plays a key role in the pathogenicity of severely ill COVID-19 patients, as previous studies have shown
245 [27]. On the Quantra QStat, based on response in normal healthy individuals, the reference range is 93% to
246 100%. In our cohort tested for CSL (n=37; 11 with adverse events), only 4 patients (1 with adverse events)
247 showed a value below the lower limit of normal, suggesting hyperfibrinolysis. Although for the QStat CSL
248 parameter a cut-off for fibrinolysis shutdown has not been determined, it is interesting to observe that the
249 proportion with the maximum CSL value of 100% was significantly higher in the patients with an adverse
250 event (63.6% vs. 19.2%; $P=0.018$). This finding suggests the presence of fibrinolysis resistance in support
251 of previous findings that attributed the hypercoagulability of COVID-19 patients to this phenomenon [28–
252 30].

253 Many of these parameters, both inflammation and coagulation, have been proposed as promising
254 prognostic markers to help us predict the risk of COVID-19 patients. In particular, many studies have
255 focused on D-dimer as an indicator of poor prognosis [20,31]. However, the prognostic value of D-dimer
256 has several limitations such as long analysis times, highlighting the need to identify other powerful markers.
257 On the other hand, increased clot stiffness has been observed especially in patients with ARDS or ICU
258 admission, revealing a possible association between these parameters and a worse prognosis of the disease
259 [32]. Nevertheless, the prognostic value of clot stiffness measured by VET techniques has not yet been
260 extensively studied. Our results demonstrate that clot stiffness parameters measured by Quantra® had a high
261 prognostic value according to ROC analysis. In particular, fibrinogen contribution to clot stiffness (FCS)
262 had the highest AUC compared to other parameters strongly associated with worse prognosis such as age
263 or D-dimer. These findings highlight the potential use of this marker as predictor of poor prognosis in
264 COVID-19 patients.

265 One of the limitations of our study is, however, that patients were analyzed only at the time of
266 diagnosis. Previous studies have shown that the predictive value of D-dimer on the risk of death is much
267 higher when measured just before the clinical outcome compared to the time of diagnosis, suggesting the
268 importance of dynamically monitoring D-dimer levels to detect thrombotic complications and thus reduce
269 the mortality rate of patients [20]. The results of our study, which found that FCS has a higher predictive
270 value for an adverse event than D-dimer, indicate that FCS may also be an important parameter to monitor,
271 especially in COVID-19 patients with elevated FCS at hospital admission. In this study we also observed
272 that both elevated FCS and D-dimer were significantly more strongly associated with patients with a worse
273 prognosis, suggesting the joint use of both parameters as a predictor of risk.

274 In summary, we can conclude from this study that the use of the sonorheometry VET technique allows
275 a global analysis of the hemostatic status of COVID-19 patients in a rapid and efficient way, including clot
276 stiffness parameters (CS, PCS, FCS, CSL) that are not routinely measured by standard laboratory tests.
277 The implementation of this technique would allow for a more accurate diagnosis of patients on admission,
278 helping in patient triage. By using this technique, we were able to detect that COVID-19 patients with
279 higher clot stiffness showed a worse prognosis, especially due to the higher contribution of fibrinogen.
280 Although further studies are needed to confirm these findings, these results show that the detection of FCS
281 at admission could be of particular interest in the clinical management of COVID-19 patients and could
282 also contribute to the development of new therapeutic strategies thanks to the numerous anticoagulant
283 agents currently available.

284
285 **AUTHOR CONTRIBUTIONS:** Conceptualization, F.J.L.-J, M.I.M.-P and I.F.-B; Methodology, F.J.L.-
286 J, I.M.-G, I.F.-B and A.M; Software, F.J.L.-J and A.M; Validation, S.M.-T, I.F.-B and A.M; Formal
287 analysis, F.J.L.-J, I.F.-B and A.M; Investigation, F.J.L.-J, S.M.-T, A.D.-M, J.M.R.-I and A.M; Data
288 curation, A.D.-M, I.F.-B and A.M; Writing – original draft preparation, F.J.L.-J, I.F.-B and A.M, Writing
289 – review and editing, all authors; Visualization, all authors; Supervision; F.J.L.-J and I.F.-B; Project
290 administration, F.J.L.-J; Funding acquisition, F.J.L.-J; All authors have read and agreed to the published
291 version of the manuscript.

292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350

ACKNOWLEDGEMENTS: The authors would like to thank to Beatriz Gago Caballero, Jessica Aguilera Rodríguez, Margarita López Quintero and Cristina Montes López from the Hospital Regional Universitario of Málaga, Spain, for their technical assistance. We would also like to thank all the nurses in the infectious diseases area of this hospital for their technical assistance. The study has been carried out in cooperation with Hemosonics but the company had no influence on decision to publish.

CONFLICTS OF INTEREST: The authors declare no conflict of interest.

REFERENCES:

1. World Health Organization WHO Coronavirus (COVID-19) Dashboard Available online: <https://covid19.who.int>.
2. Becker, R.C. COVID-19 update: Covid-19-associated coagulopathy. *J. Thromb. Thrombolysis* **2020**, *50*, 54–67, doi:10.1007/s11239-020-02134-3.
3. Tang, N.; Li, D.; Wang, X.; Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J. Thromb. Haemost.* **2020**, *18*, 844–847, doi:10.1111/jth.14768.
4. Cui, S.; Chen, S.; Li, X.; Liu, S.; Wang, F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J. Thromb. Haemost.* **2020**, *18*, 1421–1424, doi:10.1111/jth.14830.
5. Herold, T.; Jurinovic, V.; Arnreich, C.; Lipworth, B.J.; Hellmuth, J.C.; von Bergwelt-Baildon, M.; Klein, M.; Weinberger, T. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. *J. Allergy Clin. Immunol.* **2020**, *146*, 128–136.e4, doi:10.1016/j.jaci.2020.05.008.
6. Kwee, R.M.; Adams, H.J.A.; Kwee, T.C. Pulmonary embolism in patients with COVID-19 and value of D-dimer assessment: a meta-analysis. *Eur. Radiol.* **2021**, doi:10.1007/s00330-021-08003-8.
7. Hunt, B.J.; Levi, M. Re The source of elevated plasma D-dimer levels in COVID-19 infection. *Br. J. Haematol.* **2020**, *190*, doi:10.1111/bjh.16907.
8. Thachil, J. All those D-dimers in COVID-19. *J. Thromb. Haemost.* **2020**, *18*, 2075–2076, doi:10.1111/jth.14939.
9. Manfredini, R. D-dimer for the diagnosis of acute venous thromboembolism in the emergency department: a Janus-face marker. *Intern. Emerg. Med.* **2006**, *1*, 54–58, doi:10.1007/BF02934723.
10. Kabrhel, C.; Mark Courtney, D.; Camargo, C.A.; Plewa, M.C.; Nordenholz, K.E.; Moore, C.L.; Richman, P.B.; Smithline, H.A.; Beam, D.M.; Kline, J.A. Factors Associated With Positive D-dimer Results in Patients Evaluated for Pulmonary Embolism. *Acad. Emerg. Med.* **2010**, *17*, 589–597, doi:10.1111/j.1553-2712.2010.00765.x.
11. Harahsheh, Y.; Duff, O.C.; Ho, K.M. Thromboelastography Predicts Thromboembolism in Critically Ill Coagulopathic Patients*. *Crit. Care Med.* **2019**, *47*, 826–832, doi:10.1097/CCM.0000000000003730.
12. Bareille, M.; Hardy, M.; Douxfils, J.; Roullet, S.; Lasne, D.; Levy, J.H.; Stépanian, A.; Susen, S.; Frère, C.; Lecompte, T.; et al. Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review. *J. Clin. Med.* **2021**, *10*, 1740, doi:10.3390/jcm10081740.
13. Ferrante, E.A.; Blasier, K.R.; Givens, T.B.; Lloyd, C.A.; Fischer, T.J.; Viola, F. A Novel Device for the Evaluation of Hemostatic Function in Critical Care Settings. *Anesth. Analg.* **2016**, *123*, 1372–1379, doi:10.1213/ANE.0000000000001413.
14. Ranucci, M.; Ballotta, A.; Di Dedda, U.; Bayshnikova, E.; Dei Poli, M.; Resta, M.; Falco, M.; Albano, G.; Menicanti, L. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. *J. Thromb. Haemost.* **2020**, *18*, 1747–1751, doi:10.1111/jth.14854.
15. Masi, P.; Hékimian, G.; Lejeune, M.; Chommeloux, J.; Desnos, C.; Pineton De Chambrun, M.; Martin-Toutain, I.; Nieszkowska, A.; Lebreton, G.; Bréchet, N.; et al. Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19–Associated Coagulopathy. *Circulation* **2020**, *142*, 611–614, doi:10.1161/CIRCULATIONAHA.120.048925.
16. World Health Organization COVID-19 Clinical management: living guidance Available online: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>.
17. Groves, D.S.; Winegar, D.A.; Fernandez, L.G.; Huffmyer, J.L.; Viola, F. Comparison of Coagulation Parameters in Arterial and Venous Blood in Cardiac Surgery Measured Using the Quantra System. *J. Cardiothorac. Vasc. Anesth.* **2019**, *33*, 976–984,

- 351 doi:10.1053/j.jvca.2018.08.201.
352 18. Michelson, E.A.; Cripps, M.W.; Ray, B.; Winegar, D.A.; Viola, F. Initial clinical experience with
353 the Quantra QStat System in adult trauma patients. *Trauma Surg. Acute Care Open* **2020**, *5*,
354 e000581, doi:10.1136/tsaco-2020-000581.
355 19. Alsahab, M.; Beishon, L.; Brown, B.; Burn, E.; Burton, J.K.; Cox, N.; Dani, M.; Elhadi, M.;
356 Freshwater, S.; Gaunt, V.; et al. Age and frailty are independently associated with increased
357 COVID-19 mortality and increased care needs in survivors: results of an international multi-centre
358 study. *Age Ageing* **2021**, doi:10.1093/ageing/afab026.
359 20. He, X.; Yao, F.; Chen, J.; Wang, Y.; Fang, X.; Lin, X.; Long, H.; Wang, Q.; Wu, Q. The poor
360 prognosis and influencing factors of high D-dimer levels for COVID-19 patients. *Sci. Rep.* **2021**,
361 *11*, 1830, doi:10.1038/s41598-021-81300-w.
362 21. Guzik, T.J.; Mohiddin, S.A.; Dimarco, A.; Patel, V.; Savvatis, K.; Marelli-Berg, F.M.; Madhur,
363 M.S.; Tomaszewski, M.; Maffia, P.; D'Acquisto, F.; et al. COVID-19 and the cardiovascular
364 system: implications for risk assessment, diagnosis, and treatment options. *Cardiovasc. Res.* **2020**,
365 *116*, 1666–1687, doi:10.1093/cvr/cvaa106.
366 22. Guo, W.; Li, M.; Dong, Y.; Zhou, H.; Zhang, Z.; Tian, C.; Qin, R.; Wang, H.; Shen, Y.; Du, K.; et
367 al. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes.*
368 *Metab. Res. Rev.* **2020**, *36*, doi:10.1002/dmrr.3319.
369 23. Bartziokas, K.; Kostikas, K. Lactate dehydrogenase, COVID-19 and mortality. *Med. Clin. (Barc).*
370 **2021**, *156*, 37, doi:10.1016/j.medcli.2020.07.043.
371 24. Gergj, M.; Goodwin, A.; Freeman, K.; Colovos, C.; Volod, O. Viscoelastic hemostasis assays in
372 septic, critically ill coronavirus disease 2019 patients: a practical guide for clinicians. *Blood*
373 *Coagul. Fibrinolysis* **2021**, *32*, 225–228, doi:10.1097/MBC.0000000000000999.
374 25. Hartmann, J.; Ergang, A.; Mason, D.; Dias, J.D. The Role of TEG Analysis in Patients with
375 COVID-19-Associated Coagulopathy: A Systematic Review. *Diagnostics* **2021**, *11*, 172,
376 doi:10.3390/diagnostics11020172.
377 26. Baryshnikova, E.; Di Dedda, U.; Ranucci, M. A Comparative Study of SEER Sonorheometry
378 Versus Standard Coagulation Tests, Rotational Thromboelastometry, and Multiple Electrode
379 Aggregometry in Cardiac Surgery. *J. Cardiothorac. Vasc. Anesth.* **2019**, *33*, 1590–1598,
380 doi:10.1053/j.jvca.2019.01.011.
381 27. Manne, B.K.; Denorme, F.; Middleton, E.A.; Portier, I.; Rowley, J.W.; Stubben, C.; Petrey, A.C.;
382 Tolley, N.D.; Guo, L.; Cody, M.; et al. Platelet gene expression and function in patients with
383 COVID-19. *Blood* **2020**, *136*, 1317–1329, doi:10.1182/blood.2020007214.
384 28. Ibañez, C.; Perdomo, J.; Calvo, A.; Ferrando, C.; Reverter, J.C.; Tassies, D.; Blasi, A. High D
385 dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there? *J.*
386 *Thromb. Thrombolysis* **2021**, *51*, 308–312, doi:10.1007/s11239-020-02226-0.
387 29. Görlinger, K.; Almutawah, H.; Almutawaa, F.; Alwabari, M.; Alsultan, Z.; Almajed, J.; Alwabari,
388 M.; Alsultan, M.; Shahwar, D.; Yassen, K.A. The role of rotational thromboelastometry during the
389 COVID-19 pandemic: a narrative review. *Korean J. Anesthesiol.* **2021**, *74*, 91–102,
390 doi:10.4097/kja.21006.
391 30. Meizoso, J.P.; Moore, H.B.; Moore, E.E. Fibrinolysis Shutdown in COVID-19: Clinical
392 Manifestations, Molecular Mechanisms, and Therapeutic Implications. *J. Am. Coll. Surg.* **2021**,
393 doi:10.1016/j.jamcollsurg.2021.02.019.
394 31. Long, H.; Nie, L.; Xiang, X.; Li, H.; Zhang, X.; Fu, X.; Ren, H.; Liu, W.; Wang, Q.; Wu, Q. D-
395 Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor
396 Prognosis. *Biomed Res. Int.* **2020**, *2020*, 1–10, doi:10.1155/2020/6159720.
397 32. Vlot, E.A.; Van den Dool, E.J.; Hackeng, C.M.; Sohne, M.; Noordzij, P.G.; Van Dongen, E.P.A.
398 Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive
399 care unit. *Thromb. Res.* **2020**, *196*, 1–3, doi:10.1016/j.thromres.2020.07.035.
400
401